Phase 2 N=58 Regimen Optimization Study
Kidney Transplantation
Primary: Percentage of Clinically-suspected Biopsy-proven Acute Rejection (CSBPAR) at 6 Months — 7.7; 9.4 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer
Recurrent Small Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) — 2.1; 3.3 months
Phase 2 N=62 Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
Non-Small Cell Lung Cancer
Primary: Objective Response Rate — 6; 14; 5; 14 Participants — p=0.73
Phase 2 N=36 A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma
Metastatic Neuroblastoma
Primary: Comparison of the Number of Lesions Detected as Positive by [123I]mIBG Planar Scintigraphy Which Are Also Considered Positive With [124I]mIBG PET/CT. — 714; 405 Lesions…
Phase 2 N=41 (C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Events — 5; 4; 2; 6 Participants
Phase 2 N=194 A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate
Rheumatoid Arthritis
Primary: Treatment Phase: Percentage of Participants Who Achieved an American College of Rheumatology 20 (ACR20) Response at Week 12 Based on Non-responder Imputation (NRI)…
Phase 2 N=10 PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Chronic Phase Myelofibrosis · Primary Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis
Primary: European Leukemia Net -International Working Group (ELN-IWG) Criteria — 0 Participants
Phase 2 N=19 Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
Metastatic Transitional Cell Carcinoma of the Urothelium
Primary: Percentage of Participants With Progression Free Survival (PFS) at 2 Months — 54 % of participants with PFS
Phase 2 N=35 Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Progression-Free Survival (PFS) Rate at 24 Weeks — 11.4 percentage of participants
Phase 2 N=116 Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise
Insulin · Exercise
Primary: Number of Participants With Manifestation of Any Symptom at Any Point During the Protocol — 4; 6; 6; 4 Participants
Phase 2 N=50 Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Primary: Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment) — 5.6; 5.5 months
Phase 2 N=44 Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
Graft Versus Host Disease · Hematopoietic Stem Cell Transplantation · Leukemia
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 6; 6; 6; 6 Participants
Phase 2 N=200 A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Colorectal Cancer
Primary: Disease Control Rate — 34.5; 36.6; 25.6 Percentage of participants
Phase 2 N=5 Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI
Activated PI3K-delta Syndrome
Primary: Number of Participants With Any Serious Adverse Events (SAEs) and Any Non-serious Adverse Events (Non-SAEs) — 5; 0 Participants
Phase 2 N=30 Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
Iron Overload Due to Repeated Red Blood Cell Transfusions
Primary: The Percentage of Patients in Each Treatment Group Who Experience Post-dose Increases in Liver Enzyme Levels That Are Considered a Safety Concern. — 0; 0; 0; 0…